Aptose Biosciences Inc. (NASDAQ:APTO) stock shows decreases of -10.39% and traded at a price of $2.07 in preceding trading session.
Aptose Biosciences Inc. (APTO) reported that the U.S. FDA has granted orphan drug designation to CG’806, a highly potent pan-FLT3/pan-BTK inhibitor, for the treatment of patients with acute myeloid leukemia (AML). AML is a particularly devastating cancer of the blood and bone marrow and is the most common type of acute leukemia among adults, with an annual incidence of around 21,000 patients and causing more than 10,000 deaths each year in the U.S.
Chairman, President and CEO, William G. Rice said, “We are pleased that the FDA has recognized the unique potential of CG’806 to address AML and has assigned CG’806 the status of orphan drug designation. “Results from non-clinical studies that we and our research collaborators have generated are promising and give reason for our eagerness to begin clinical trials in both AML and B-Cell malignancies in 2018.”
AML cells utilize multiple forms of the FLT3 receptor tyrosine kinase and other pathways to promote rapid proliferation and to escape the inhibitory activities of many therapeutics. CG’806 is a highly potent inhibitor that simultaneously targets all known forms of FLT3 and other key oncogenic pathways that drive the proliferation of AML cancer cells, thereby providing CG’806 with a broad range of activity against AML and a strategy to delay mutational escape.
Its 52-week range quite noticeable, lower range was $165.38% and hit highest level of $-19.77%. The overall volume in the last trading session was 842821 shares. The liquidity position of firm is on noticeable level, as its current ratio was calculated as 8.30 at the same time as its debt to equity ratio stands at 0.00.
Shares of INSYS Therapeutics, Inc. (NASDAQ:INSY) at the time when day-trade ended the stock finally plummeted -2.80% to close at $7.97. INSYS Therapeutics, Inc. (INSY) reported that U.S. FDA has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.
The senior VP of regulatory affairs for INSYS Therapeutics, Steve Sherman said, “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any authorized products available . “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.”
“We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said SaeedMotahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a important milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.”
The volatility tends to amount of risk or uncertainty about size of changes in a security’s value; a higher volatility denotes that a security’s value can potentially be spread out over a larger range of values. The price volatility of INSY was 9.23% for a week and 7.82% for a month as well as price volatility’s Average True Range for 14 days was 0.53. Shares price isolated positively from its 50 days moving average with 32.06% and remote negatively from 200 days moving average with -17.77%.